PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 197 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $138,858 | -7.9% | 4,526 | +20.3% | 0.01% | 0.0% |
| Q2 2023 | $150,743 | +6.5% | 3,762 | +8.5% | 0.01% | 0.0% |
| Q1 2023 | $141,529 | +9.4% | 3,468 | 0.0% | 0.01% | +20.0% |
| Q4 2022 | $129,426 | -29.7% | 3,468 | 0.0% | 0.01% | -37.5% |
| Q3 2022 | $184,000 | -8.9% | 3,468 | 0.0% | 0.01% | -11.1% |
| Q2 2022 | $202,000 | -23.8% | 3,468 | 0.0% | 0.01% | -10.0% |
| Q1 2022 | $265,000 | +26.8% | 3,468 | 0.0% | 0.01% | +42.9% |
| Q4 2021 | $209,000 | +7.7% | 3,468 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $194,000 | -7.6% | 3,468 | 0.0% | 0.01% | -12.5% |
| Q2 2021 | $210,000 | -13.6% | 3,468 | 0.0% | 0.01% | -11.1% |
| Q1 2021 | $243,000 | +11.5% | 3,468 | -4.7% | 0.01% | -10.0% |
| Q4 2020 | $218,000 | -0.5% | 3,640 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $219,000 | +14.7% | 3,640 | 0.0% | 0.01% | +11.1% |
| Q2 2020 | $191,000 | +56.6% | 3,640 | 0.0% | 0.01% | +28.6% |
| Q1 2020 | $122,000 | -21.8% | 3,640 | +5.5% | 0.01% | 0.0% |
| Q4 2019 | $156,000 | +19.1% | 3,449 | 0.0% | 0.01% | +16.7% |
| Q3 2019 | $131,000 | -12.7% | 3,449 | 0.0% | 0.01% | -14.3% |
| Q2 2019 | $150,000 | +14.5% | 3,449 | 0.0% | 0.01% | +16.7% |
| Q1 2019 | $131,000 | -11.5% | 3,449 | 0.0% | 0.01% | -25.0% |
| Q4 2018 | $148,000 | -12.9% | 3,449 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $170,000 | +53.2% | 3,449 | 0.0% | 0.01% | +60.0% |
| Q2 2018 | $111,000 | +3.7% | 3,449 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $107,000 | -31.8% | 3,449 | 0.0% | 0.01% | -28.6% |
| Q4 2017 | $157,000 | +19.8% | 3,449 | 0.0% | 0.01% | +16.7% |
| Q3 2017 | $131,000 | -20.6% | 3,449 | 0.0% | 0.01% | -25.0% |
| Q2 2017 | $165,000 | +14.6% | 3,449 | +9.6% | 0.01% | +14.3% |
| Q1 2017 | $144,000 | -33.3% | 3,147 | +11.9% | 0.01% | -53.3% |
| Q4 2015 | $216,000 | -23.9% | 2,812 | -12.0% | 0.02% | -21.1% |
| Q1 2015 | $284,000 | +0.4% | 3,195 | 0.0% | 0.02% | 0.0% |
| Q4 2014 | $283,000 | -8.7% | 3,195 | 0.0% | 0.02% | -13.6% |
| Q3 2014 | $310,000 | +5.8% | 3,195 | 0.0% | 0.02% | +4.8% |
| Q2 2014 | $293,000 | – | 3,195 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
| Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
| GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
| Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
| Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
| Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
| Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |